340 related articles for article (PubMed ID: 23123106)
1. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults.
Seiberling M; Bologa M; Brookes R; Ochs M; Go K; Neveu D; Kamtchoua T; Lashley P; Yuan T; Gurunathan S
Vaccine; 2012 Dec; 30(52):7455-60. PubMed ID: 23131206
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study.
Brooks WA; Chang LJ; Sheng X; Hopfer R;
Vaccine; 2015 Aug; 33(36):4610-7. PubMed ID: 26143615
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.
Kamtchoua T; Bologa M; Hopfer R; Neveu D; Hu B; Sheng X; Corde N; Pouzet C; Zimmermann G; Gurunathan S
Vaccine; 2013 Jan; 31(2):327-33. PubMed ID: 23153437
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.
Leroux-Roels I; Devaster JM; Leroux-Roels G; Verlant V; Henckaerts I; Moris P; Hermand P; Van Belle P; Poolman JT; Vandepapelière P; Horsmans Y
Vaccine; 2015 Jan; 33(4):577-84. PubMed ID: 24176494
[TBL] [Abstract][Full Text] [Related]
6. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
[TBL] [Abstract][Full Text] [Related]
7. A bivalent pneumococcal histidine triad protein D-choline-binding protein A vaccine elicits functional antibodies that passively protect mice from Streptococcus pneumoniae challenge.
Ochs MM; Williams K; Sheung A; Lheritier P; Visan L; Rouleau N; Proust E; de Montfort A; Tang M; Mari K; Hopfer R; Gallichan S; Brookes RH
Hum Vaccin Immunother; 2016 Nov; 12(11):2946-2952. PubMed ID: 27392182
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.
Pauksens K; Nilsson AC; Caubet M; Pascal TG; Van Belle P; Poolman JT; Vandepapelière PG; Verlant V; Vink PE
Clin Vaccine Immunol; 2014 May; 21(5):651-60. PubMed ID: 24599529
[TBL] [Abstract][Full Text] [Related]
9. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.
Frey SE; Lottenbach KR; Hill H; Blevins TP; Yu Y; Zhang Y; Brenneman KE; Kelly-Aehle SM; McDonald C; Jansen A; Curtiss R
Vaccine; 2013 Oct; 31(42):4874-80. PubMed ID: 23916987
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial.
Prymula R; Pazdiora P; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 May; 32(25):3025-34. PubMed ID: 24699466
[TBL] [Abstract][Full Text] [Related]
11. Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.
Verhoeven D; Perry S; Pichichero ME
Clin Vaccine Immunol; 2014 Aug; 21(8):1037-45. PubMed ID: 24850621
[TBL] [Abstract][Full Text] [Related]
12. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model.
Xu Q; Pryharski K; Pichichero ME
Vaccine; 2017 Jan; 35(2):337-344. PubMed ID: 27919628
[TBL] [Abstract][Full Text] [Related]
13. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants.
Ljutic B; Ochs M; Messham B; Ming M; Dookie A; Harper K; Ausar SF
Vaccine; 2012 Apr; 30(19):2981-8. PubMed ID: 22381074
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model.
Verhoeven D; Xu Q; Pichichero ME
Vaccine; 2014 May; 32(26):3205-10. PubMed ID: 24731814
[TBL] [Abstract][Full Text] [Related]
15. Passive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies.
Brookes RH; Ming M; Williams K; Hopfer R; Gurunathan S; Gallichan S; Tang M; Ochs MM
Hum Vaccin Immunother; 2015; 11(7):1836-9. PubMed ID: 25912273
[TBL] [Abstract][Full Text] [Related]
16. Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.
Ren D; Almudevar AL; Pichichero ME
Hum Vaccin Immunother; 2015; 11(2):489-97. PubMed ID: 25692218
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study.
Hammitt LL; Campbell JC; Borys D; Weatherholtz RC; Reid R; Goklish N; Moulton LH; Traskine M; Song Y; Swinnen K; Santosham M; O'Brien KL
Vaccine; 2019 Dec; 37(51):7482-7492. PubMed ID: 31629570
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
Ruiz-Palacios GM; Guerrero ML; Hernández-Delgado L; Lavalle-Villalobos A; Casas-Muñoz A; Cervantes-Apolinar Y; Moreira M; Schuerman L
Hum Vaccin; 2011 Nov; 7(11):1137-45. PubMed ID: 22048109
[TBL] [Abstract][Full Text] [Related]
20. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
